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Abstract: Doxorubicin (DOX) is an anticancer drug commonly used in treating cancer; however, it has
severe cytotoxicity effects. To overcome both the adverse effects of the drug and mineral deficiency
(i.e., hypomagnesemia) experienced by cancer patients, we have developed magnesium oxide (MgO)
nanoflakes as drug carriers and loaded them with DOX for use as a targeted drug delivery (TDD)
system for potential application in cancer therapy. The synthesis employed herein affords pure,
highly porous MgO nanoparticles that are void of the potentially harmful metal contaminants often
discussed in the literature. Purposed for dual therapy, the nanoparticles exhibit an impressive
90% drug loading capacity with pH dependent drug releasing rates of 10% at pH 7.2, 50.5% at pH
5.0, and 90.2% at pH 3. Results indicate that therapy is achievable via slow diffusion where MgO
nanoflakes degrade (i.e., dissolve) under acidic conditions releasing the drug and magnesium ions
to the cancerous region. The TDD system therefore minimizes cytotoxicity to healthy cells while
supplying magnesium ions to overcome hypomagnesemia.
Keywords: MgO nanoparticles; doxorubicin; nanoflakes; drug delivery

1. Introduction
Cancer is one of the leading causes of death, accounting for an annual mortality rate of 163.5 per
100,000 men and women as per 2011–2015 death statistics [1]. Chemotherapy stands as one of the
most important treatment strategies. However, chemotherapy is associated with severe drawbacks.
Among those, toxicity to healthy cells is a major disadvantage as it leads to complications such as hair
loss, nausea, fatigue, and increased risk of infection [2–4]. As such, development of non-toxic drug
carriers capable of high drug encapsulation with minimal cargo loss during circulation, yet slow and
steady release solely at the cancer cells is desirable.
Cancer cells have much higher metabolic rates than healthy normal cells, tending to consume more
nutrients and oxygen [5]. An insufficient supply of oxygen to cancer cells causes acidosis producing
lactic acid at the extracellular medium. In turn, the extracellular pH of cancer cells is in the range of
6.2–6.9, while those of intracellular medium are in the range of 7.12–7.65 [6]. Therefore, the extracellular
medium of cancerous cells are slightly acidic and any non-toxic material that would slowly dissolve in
such conditions would be useful as drug carriers.
Non-toxic inorganic nanoparticles, such as CaCO3 and MgO, which dissolve at slightly acidic
conditions, fulfill these requirements and can be used as drug carriers for transporting anticancer
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drugs for targeted delivery (TD) and slow release (SR). Since these materials do not dissolve at the
physiological pH of blood (7.2), drug release is less likely to occur during the transport process.
Instead, it would happen slowly at the extracellular medium of cancerous cells. Such a strategy
is useful in reducing cytotoxicity of the drugs to healthy cells. In addition, it helps to minimize
the dosage requirement and wastage of the drug while enhancing its efficacy and bio-availability.
Recently, we tested the hypothesis using model drug copper bis(8-hydroxyquinoline) in hydroxyapatite
nanoparticles and found it to be a viable approach to TD [6]. We then developed vaterite forms of
CaCO3 nanoparticles and loaded them with cisplatin for TD and SR of the drug at the cancerous
cells [7,8]. CaCO3 nanoparticles encapsulated with cisplatin showed 70 wt% drug loading capacity and
cargo releasing rates of 0.18%, 0.98%, 12.0%, 13.6%, and 16.4% at pH values 8, 7, 6, 5, and 4, respectively,
thus showing appreciable rates at acidic pH values below 7.0 due to slow dissolution of the CaCO3
nanoparticle carriers, and thereby supplying both the drug and calcium ions.
Inspired by Gan et al. [9], we advanced this study towards highly porous MgO nanoparticles
exhibiting a flake-like morphology as a dual therapy agent. Counter to previously reported works [10],
our MgO nanoparticles were synthesized [11,12] to produce pure materials void of potentially
toxic metal cation contaminants [13]. The nanoparticles were characterized to confirm such, and
their application as a pH-dependent TD drug carrier for the anticancer drug DOX was evaluated.
For this study, DOX was utilized as a valuable anticancer drug that requires a localized release.
DOX has been shown to affect multiple organs with damage to the heart and vascular system as the
most common side effect [14]. A schematic illustrating the carrier design is shown in Figure 1. At the
extracellular membrane of cancerous cells, the MgO carrier dissolves slowly, releasing both the DOX
and magnesium ions. The latter acts an additional advantage to the properties of the drug carrier.
Cancer cells have a propensity to absorb large amounts of magnesium ions, thereby depleting the
magnesium in the surrounding biological environment. Such a decrease in magnesium levels in the
blood leads to the development of an anemic condition known as hypomagnesemia [15–17]. This is
also one of the most common side effects of chemotherapeutic drugs (e.g., cisplatin, cyclosporine,
enzastaurin) [16]. The condition occurs when the blood magnesium concentration is reduced to below
1.8 mg/dL (0.70 mmol/L). A lack of magnesium ions can effect calcium-potassium regulation, cardiac
and neural conduction, and adenosine triphosphate (ATP) metabolism. In addition, many enzymes that
influence the metabolism of various biomolecules require magnesium ions as a source [17]. The drug
carrier developed herein has the potential to act as a magnesium supplement to treat hypomagnesemia,
as well as a cancer therapy agent.
2. Materials and Methods
Cetyltrimethylammonium chloride (CTAC) (98% purity), nitric acid (68% assay), barium chloride
(99% assay), potassium chloride (98% assay), potassium monohydrogen orthophosphate (99% assay),
sodium Chloride (99% assay), sodium bicarbonate (99% assay), magnesium chloride (99% assay),
calcium chloride (98% assay), sodium sulfate (99% assay), sodium acetate (99% assay), potassium
hydrogen phthalate (KHP) (99% assay), ethanol (99% purity), and acetic acid (99.5% assay) were
purchased from Sigma-Aldrich (St. Louis, MO, USA). These chemicals were of analytical grade
and used without further purification. Doxorubicin vial bottles containing 50 mg powder were
purchased from Sri Lanka Pharmacy, Kandy, Sri Lanka. Bittern from Puttalam salt Ltd., Palavi,
Puttalam, Sri Lanka (N 7.979826◦ , E 79.828478◦ ) was used as a magnesium source and characterized by
specific gravity measured using hydrometer according to the ASTM International standards (D1429)
(ASTM International, 2017). Solutions of specific gravity >1.25 were used. For a 200.0 mL sample,
5.0 mL of 1.0 mol L−1 HNO3 was added and refluxed for 1 h to form a homogenous mixture. The sample
was then treated with 0.5 mol L−1 barium chloride to remove sulphate ions. After precipitation,
the suspension was filtered, and clear filtrate was collected. As the secondary magnesium source,
dolomite obtained from marble quarry in Madawala Ulpatha, Sri Lanka (N 7.573308◦ , E 80.626237◦ ) was
used. 15.0 g of dolomite was mechanically crushed and ground in a sintered crucible. The powdered
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sample was sieved to obtain a portion of particles less than 150 µm in size. These particles were heated
in size. These particles were heated at 1000 °C for 2 h to produce calcined dolomite. Additional details
at 1000 ◦ C for 2 h to produce calcined dolomite. Additional details are provided in the supporting
are provided in the supporting information (SI).
information (SI).

Figure 1. Schematic representation of MgO-DOX TDD system: Electrostatic interactions and hydrogen
Figure 1. Schematic representation of MgO-DOX TDD system: Electrostatic interactions and
bonds facilitating binding of DOX on to MgO surface (a) and drug and Mg2+ slow release
at slightly
hydrogen bonds facilitating binding of DOX on to MgO surface (a) and drug and Mg2+ slow release
acidic conditions prevailing in cancer cells (b). After slow diffusion of MgO nano flakes from blood
at slightly acidic conditions prevailing in cancer cells (b). After slow diffusion of MgO nano flakes
vessel to cancer cell, DOX molecules interact with mutated DNA and Mg2+ act2+as a nutrient to
from blood vessel to cancer cell, DOX molecules interact with mutated DNA and Mg act as a nutrient
hypomagnesemia (c).
to hypomagnesemia (c).

MgO nanoparticles were synthesized as follows [18,19]: First, 100.0 mL of pre-treated bittern
MgO nanoparticles were synthesized as follows [18,19]: First, 100.0 mL of pre-treated bittern
solution was taken to a 500 mL beaker and 1.0 mL of 1 mmol L−1 CTAC surfactant was added and
solution was taken to a 500 mL beaker and 1.0 mL of 1 mmol L−1 CTAC surfactant was added and
stirred for 1 h. 2.0 g of calcined dolomite was then slowly added to the reaction mixture and thoroughly
stirred for 1 h. 2.0 g of calcined dolomite was then slowly added to the reaction mixture and
stirred for 12 h. The undissolved part was allowed to settle to the bottom of the beaker and the upper
thoroughly stirred for 12 h. The undissolved part was allowed to settle to the bottom of the beaker
portion was composed of a gel. The gel was separated by filtration and heated in an oven at 100 ◦ C for
and the upper portion was composed of a gel. The gel was separated by filtration and heated in an
24 h. The dry powder thus obtained was washed several times with distilled water and 5% ethanol.
oven at 100 °C for 24 h. The dry powder thus obtained was washed several times with distilled water
The product obtained was dried and calcined at 450 ◦ C for 2 h in a furnace.
and 5% ethanol. The product obtained was dried and calcined at 450 °C for 2 h in a furnace.
Fourier Transform Infrared (FT-IR) spectra of each product were recorded using a iS50 FT-IR
Fourier Transform Infrared (FT-IR) spectra of each product were recorded using a iS50 FT-IR
instrument (Thermos scientific, Waltham, MA, USA) coupled with Attenuated Total Reflectance (ATR)
instrument (Thermos scientific, Waltham,
MA, USA) coupled with Attenuated Total Reflectance
technology. Samples were dried at 100 ◦ C, and placed in a dry desiccator under a vacuum prior to
(ATR) technology. Samples were dried at 100 °C, and placed in a dry desiccator under a vacuum
analyses. The crystalline phases of the powdered products were analyzed by X-ray Diffractometry
prior to analyses. The crystalline phases of the powdered products were analyzed by X-ray
(XRD) using a D5000 Powder X-ray Diffractometer (Siemens, Munich, Germany) (Cu Kα radiation,
Diffractometry (XRD) using a D5000 Powder X-ray Diffractometer (Siemens, Munich, Germany) (Cu
λ = 0.1540562 nm, scan rate 1◦ min−1 ). The XRD patterns were analyzed with the aid of the ICDD PDF
Kα radiation, λ = 0.1540562 nm, scan rate 1° min−1). The XRD patterns were analyzed with the aid of
the ICDD PDF 2 database. The average crystallite sizes of magnesium oxide products were estimated
by applying the Scherrer equation to the major XRD peaks.
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2 database. The average crystallite sizes of magnesium oxide products were estimated by applying the
Scherrer equation to the major XRD peaks.
Morphology and average size of particles and their aggregates were examined, after sputtering
with gold particles, using an EVO LS 15 Scanning Electron Microscope (SEM, ZEISS, Germany) at
an accelerating voltage of 20 kV. OXFORD analyzer (Oxford, England) coupled with the SEM was used
to obtain energy-dispersive X-ray spectroscopic data (EDX). Particle size distribution was characterized
by Laser Light Scattering based Particle Size Analysis (CILAS Particle Size Analyzer NANO DS, France).
Nitrogen adsorption isotherms were measured at −196 ◦ C on an ASAP 2010 volumetric analyzer
(Micromeritics Inc., Norcross, GA, USA). Prior to adsorption measurements, all samples were out
gassed under the vacuum at 110 ◦ C for 2 h. Additional details are provided in the SI.
Preparation of simulated body fluid and cancer cellular fluid was carried out as follows. Simulated
body fluid (SBF) is an acellular solution with composition and concentration similar to that of
human plasma at 36.5 ◦ C. The SBF was prepared by dissolving KCl, K2 HPO4 3H2 O, NaCl, NaHCO3 ,
MgCl2 .6H2 O, CaCl2 , and Na2 SO4 in distilled water and buffering at pH 7.4 with phosphate and HCl
(1.0 M) at 36.5 ◦ C as described in a previous study [20]. The pH 5.0 buffer was prepared by mixing
0.1 M sodium acetate (35.2 mL) and 0.1 M acetic acid (14.8 mL) and diluting to 100 mL to maintain
acetate buffer in a SBF solution. The pH 3.0 buffer was prepared by mixing 0.1 M KHP (100 mL) with
0.1 M HCl (44.6 mL).
Drug loading study was performed using different concentrations of doxorubicin hydrochloride
in the range 0.1–0.5 mg/mL. 1 mg/mL of MgO nanoparticles were used with each of the solution.
A comprehensive study was carried out using 1 mg/mL solution of doxorubicin hydrochloride
prepared from dry powder by dissolving 50 mg into 50 mL of double distilled water. 1.0 g of
MgO nanoparticles were dispersed separately in 10 mL of each of these solutions. The mixture
was first sonicated for 1 h, which was followed by overnight stirring at room temperature in the dark.
The samples were centrifuged and washed several times to remove excess DOX. Centrifugation was
performed at 5000 rpm until a colorless supernatant was observed leaving a purple residue at the
bottom of the centrifuge tube. Aided by UV-Vis spectroscopy, drug loading capacity (DLC, wt.%)
and drug loading efficiency (DLE, wt.%) were calculated by measuring concentrations of DOX in the
solutions before and after loading. Additional details are provided in the SI.
In-vitro release studies were performed on prepared nanomaterials at 37 ◦ C in three different
media, i.e., (a) KHP buffer at pH 3.0 (b) acetate buffer at pH 5.0 (c) phosphate buffer at pH 7.4.
Three portions of MgO nanoparticles (50 mg) were transferred into three dialysis membranes previously
soaked overnight in 4.0 mL of buffer. After that, sealed membranes were introduced into three
separate flasks containing 100.0 mL of corresponding buffer solution (pH 7.4, pH 5.0 and pH 3.0).
Samples were shaken horizontally in a thermostat shaker at 37 ◦ C and 100 rpm. At predetermined
time intervals, a 4.0 mL sample of the medium was taken and replaced with the same amount of
fresh buffer to maintain a constant volume. The release experiments were conducted in triplicate.
The results presented are the average data of three repetitive measurements together with their
standard deviations. DOX concentration in solutions was evaluated using UV-visible absorption
spectroscopy by measuring absorbance at 253 nm since it is a narrow band with high molar absorption
coefficients [21]. Furthermore, this band position that is determined by the π → π* transition of
DOX is independent of the pH of the medium. However, the absorption band centered at 480 nm
(n → π* transition) of DOX at pH 7.0 showed red shift as the pH of the medium was decreased
(Figure S1). In order to convert absorbance data to concentrations, calibration curves were run with
DOX in corresponding buffer solutions at the same pH values by measuring absorbance at 253 nm and
the applicability of the Beer-Lambert law was verified (Figure S2). The cumulative release profile of
DOX loaded to a MgO nanoparticle was obtained via the concentration correction (the amount of DOX
in each aliquot was calculated to correct the overall cumulative releasing of DOX) of released DOX
using Equation (1).
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These nuclei grow to a certain size determined by the cavity volume. Other factors include
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interactions between the surfactants and Mg(OH)2 particles formed, and surface coverage of particles
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Figure 2. XRD pattern of before calcination (a) and after calcination of nanoparticles (b).
Figure 2. XRD pattern of before calcination (a) and after calcination of nanoparticles (b)

The XRD pattern obtained before calcination consists of Mg(OH)2 peaks at 2θ values of 33.0◦ ,
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Figure 3 shows SEM images at (a) 25,000× and (b) 50,000× magnifications. Images show a flakelike surface morphology. The flake-like morphology is obtained due to the self-assembly of CTAC
ions facilitating the formation of Mg(OH)2 precursor particles. In these dimensions, the positively
charged head of surfactant ions are stabilized by negatively charged hydroxyl ions, which are

Nanomaterials 2019, 9, 208

6 of 11

Figure 3 shows SEM images at (a) 25,000× and (b) 50,000× magnifications. Images show
a flake-like surface morphology. The flake-like morphology is obtained due to the self-assembly of
CTAC ions facilitating the formation of Mg(OH)2 precursor particles. In these dimensions, the positively
charged head of surfactant ions are stabilized by negatively charged hydroxyl ions, which are
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3.2. Pore size Distribution of MgO Nanoflakes
The N2 gas adsorption/desorption isotherm obtained for MgO nanoflakes is shown in Figure 4a.
This type of adsorption isotherm corresponds to adsorption of gas molecules onto materials with
pore sizes in the range of 1.5–100 nm. At higher pressures, the slope shows an increased uptake of
adsorbate as pores become filled with an inflection point typically occurring near completion of the
first monolayer. Figure 4b gives the pore size distribution derived from the N2 gas
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3.2. Pore size Distribution of MgO Nanoflakes
The N2 gas adsorption/desorption isotherm obtained for MgO nanoflakes is shown in Figure 4a.
This type of adsorption isotherm corresponds to adsorption of gas molecules onto materials with
pore sizes in the range of 1.5–100 nm. At higher pressures, the slope shows an increased uptake of
adsorbate as pores become filled with an inflection point typically occurring near completion of the first
monolayer. Figure 4b gives the pore size distribution derived from the N2 gas adsorption/desorption
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that the pore sizes are in the nano-range of 50% porosity. Such high porosity of MgO nanoflake
the nano-range of 50% porosity. Such high porosity of MgO nanoflake architecture is advantageous in
architecture is advantageous in accommodating large amounts of DOX molecules (vide supra).
accommodating large amounts of DOX molecules (vide supra).

Figure 4. Nitrogen adsorption isotherms (a) and the corresponding pore size distribution curve (b) for
Figure 4. Nitrogen adsorption isotherms (a) and the corresponding pore size distribution curve (b)
MgO nanoflakes.
for MgO nanoflakes.

3.3. FTIR Studies for Drug Loaded Nanoparticles
3.3. FTIR Studies for Drug Loaded Nanoparticles
The FTIR spectrum of DOX, as depicted in Figure 5a, demonstrates several bands corresponding
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The spectrum shown in Figure 5c is that of DOX-loaded MgO, which was recorded after drying
the sample at 60 ◦ C for 2 h in air. Some spectral changes such as appearance of new bands, change in
intensity of previous bands. In addition, the broadening of some bands, together with shifts in band
positions, are clearly apparent. The spectrum of parent DOX shows bands at 3700 cm−1 are due to
N–H stretching vibrations, while 1638 cm−1 are due to N–H bend vibrations of the primary amine
structure. However, in the case of DOX-loaded MgO, only a single broad band centered at 3440 cm−1
is observed and is due to the overlapping of N–H and O–H stretching vibrations. Comparison of the
spectra suggest that there are strong interactions between DOX functional groups and hydroxyl groups
of MgO nanoparticles possibly through hydrogen bonding. The appearance of characteristic bands
of DOX in the encapsulated product confirm the presence of DOX molecules on the surface of MgO
nanoparticles without any modification to DOX molecules. As such, it is possible that DOX molecules
are bound to the surface of MgO nanoparticles via the electrostatic interaction of protonated NH3 + of
DOX and O2 - sites on the surface of MgO nanoparticles as well as through hydrogen bonding between
O-H and N-H groups of DOX and O-H groups of MgO nanoparticles.

O at 1024 cm . Figure 5b represents the IR spectrum of MgO nanoparticles. The weak band appearing
at 860 cm−1 indicates the presence of bending vibrations of the intercalated metal–oxide species [22].
The band at 1441 cm−1 is assigned to Mg–O bond vibration [23]. Broad absorptions observed at 581
cm−1 are generally regarded as a surface mode associated with lattice vibrations, which illustrates the
fundamental lattice vibrations (phonon) of MgO nanoparticles due to the creation or annihilation of
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Figure 5.
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3.4. Drug Loading Capacity (DLC) and Drug Loading Efficiency (DLE)
DLC and DLE are defined as shown in Equations (2) and (3) respectively.
DLC =

amount of loaded drug
× 100%
amount of nanoparticles

(2)

DLE =

amount of loaded drug
× 100%
amount of feeding drug

(3)

Considerably high values of 90.20% and 92.44% are obtained for DLC and DLE, respectively,
for the loading of DOX on MgO nanoflake architectures. Compared to the 70% DLC obtained for
cisplatin on CaCO3 nanoparticles [8], this is a remarkable improvement in drug loading for our
carriers. Such high values are due to the high porosity (50%) generated in the architecture of MgO
nanoflakes, providing a space for DOX molecules to reside while keeping them in place through
noncovalent interactions.
3.5. Drug Releasing Studies
Kinetic analysis of drug release was performed for a 104 hour period by measuring absorbance
values at 253 nm and converting them to concentration, ct , at time, t, and correcting to cumulative
0
concentrations, ct , using Equation (1). Additionally, the increase in ionic concentration of the buffer
solutions to which DOX is released is verified by measuring electrical conductivity of the buffer
solution as a function of time. An intital slow increase of electrical conductivity followed by rapid
increase is obtained at each pH as more ions are released to the solution by slow dissolution. The rate of
increase in conductivity is much higher at low pH—presumely due to the addition of magnesium ions
releasing into the media—than that at a high pH (Figure S4). At pH 3.0, the drug is released rapidly
within the first 8 hours as MgO dissolves readily at this pH, releasing 71.23% of the drug (Figure 6).
The releasing kinetics at pH 5.0 and pH 7.4 show lower rates as MgO dissolves slowly at pH 5.0 and is
not dissolved at pH 7.4, giving rise to 17.8% and 4.23% release within the first 8 h. The percentage of
DOX released at the end of 104 h is 90.2, 50.5, and 7.4% at pH 3.0, 5.0, and 7.4 respectively. Data clearly
show that the drug released at the physiological pH value of blood is insignificant during the transport
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of DOX in the carrier and slow release is obtained at the pH of the extracellular medium of the cancer
cells. As such, MgO nanoflakes tend to entrap the drug in the cavities formed between the flakes.
The flaky morphology affords strong binding of drug molecules for safe transport towards cancer cells
where it can be released at a slow and steady rate alongside the magnesium ions. Therefore, this TDD
Nanomaterials
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system has2019,
dual9,advantages,
as it could be used to treat cancer and hypomagnesemia simultaneously.

Figure 6.
6. pH
pHdependent
dependentdrug
drug release
release of
of DOX-entrapped
DOX-entrapped MgO
MgO nanoflakes.
nanoflakes.
Figure

4. Conclusions
Conclusions
4.
In this
this work,
work, we
we report
report the
the synthesis
synthesis of
of flake-shaped
flake-shaped MgO
MgO nanoparticles
nanoparticles with
with narrow
narrow particle
particle
In
size distribution.
distribution. Nanoflakes
Nanoflakes agglomerate
agglomerate to
to form
form self-assembled
self-assembled structures
structures with
with 50%
50% porosity.
porosity.
size
Drugs
such
as
DOX
readily
bind
to
the
surfaces
of
these
nanoflakes
via
hydrogen
bonding
and
Drugs such as DOX readily bind to the surfaces of these nanoflakes via hydrogen bonding and
through
electrostatic
interactions.
The
inter-particle
spaces
of
agglomerated
nanoflakes
can
be
filled
through electrostatic interactions. The inter-particle spaces of agglomerated nanoflakes can be filled
up to
to 90.0%
90.0% (loading
(loading capacity)
capacity) with
with 92.4%
92.4% drug
drug loading
loading efficiency.
efficiency. All
All materials
materials synthesized
synthesized were
were
up
appropriately
characterized
by
several
independent
analytical
techniques
with
closely
parallel
results.
appropriately characterized by several independent analytical techniques with closely parallel
The cumulative
release kinetics
the drug
investigated
at differentatpH
values. pH
Results
corroborate
results.
The cumulative
releaseof
kinetics
of were
the drug
were investigated
different
values.
Results
the
development
of
a
novel
material
for
loading
DOX
for
pH
dependent
TDD
to
potentially
corroborate the development of a novel material for loading DOX for pH dependenttreat
TDDboth
to
hypomagnesemia
andhypomagnesemia
cancer.
potentially
treat both
and cancer.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-4991/9/2/208/s1.
Supplementary
Materials:
following
are available
onlineinatdifferent
www.mdpi.com/xxx/s1.
Figure S1: UV-VIS
Spectra ofThe
standard
solutions
of Doxorubicin
Buffer solutions atFigure
pH 3.0,S1:
5.0UV-VIS
and 7.0.
Spectra
of Calibration
standard solutions
of DoxorubicinBeer-Lambert
in different Buffer
solutions
at pH
3.0, 5.0 and
7.0. Figure S2:
Figure S2:
curves demonstrating
Law for
UV-visible
spectroscopic
determination
of
Doxorubicin
at pHdemonstrating
7.4, 5.0 and 3.0Beer-Lambert
at 253 nm. Figure
Metal hydroxide
coordination
stabilizedofstructure
with
Calibration
curves
Law S3:
for UV-visible
spectroscopic
determination
Doxorubicin
CTAC
micelle.
Figure
bufferhydroxide
solutions coordination
as a functionstabilized
of log(time).
Figurewith
S5: XRD
Pattern
of
at
pH 7.4,
5.0 and
3.0 atS4:
253Conductivity
nm. Figure S3:ofMetal
structure
CTAC
micelle.
Calcined Dolomite. Figure S6: (a) SEM image of Calcined Dolomite at 25000X magnification (b) EDX spectrum
Figure S4: Conductivity of buffer solutions as a function of log(time). Figure S5: XRD Pattern of Calcined
of Calcined Dolomite. Figure S7: Structure of Cetyltrimethylammonium chloride [CH3 (CH2 )15 N(Cl)(CH3 )3 ].
Dolomite.
FigureDegree
S6: (a) SEM
imageGravity
of Calcined
Dolomite
at 25000X
(b)atomic
EDX spectrum
of Calcined
Table S1: Baumé
of Specific
Conversion
Chart.
Tablemagnification
S2: Weight and
percentages
obtained
Dolomite.
from EDX Figure
data. S7: Structure of Cetyltrimethylammonium chloride [CH3(CH2)15N(Cl)(CH3)3]. Table S1: Baumé
Degree of Specific Gravity Conversion Chart. Table S2: Weight and atomic percentages obtained from EDX data.
Author Contributions: Conceptualization, T.R., R.M.G.R. and D.G.P.P.; methodology, T.R.; software, T.R.;
validation,
D.G.P.P., R.M.G.R.,
D.L.W.; formal
analysis,
T.R.
andD.G.P.P.;
R.M.G.R.;
investigation,
R.M.G.R.,
D.G.G.P.,
Author
Contributions:
Conceptualization,
T.R.,
R.M.G.R.
and
methodology,
T.R.;
software,
T.R .;
D.L.W.; resources, T.R.; data curation, T.R.; writing—original draft preparation, T.R., D.G.G.P., R.M.G.R., D.L.W.;
validation, D.G.P.P., R.M.G.R., D.L.W.; formal analysis, T.R and R.M.G.R; investigation, R.M.G.R., D.G.G.P.,
writing—review and editing, T.R., D.G.G.P., R.M.G.R., D.L.W.; visualization, T.R.; supervision, D.G.G.P., R.M.G.R.,
D.L.W.;
resources,
T.R.; data curation,
T.R.; writing—original
draft
preparation,
T.R.,R.M.G.R.,
D.G.G.P.,D.L.W.
R.M.G.R.,
D.L.W.; project
administration,
D.G.G.P., R.M.G.R.,
D.L.W.; funding
acquisition,
D.G.G.P.,
D.L.W.; writing—review and editing, T.R., D.G.G.P., R.M.G.R., D.L.W.; visualization, T.R.; supervision,
Funding: The authors are grateful to the financial support from National Science Foundation [Grant no.
D.G.G.P., R.M.G.R., D.L.W; project administration, D.G.G.P., R.M.G.R., D.L.W.; funding acquisition, D.G.G.P.,
TG/2016/Tec-D/02].
R.M.G.R., D.L.W.
Conflicts of Interest: The authors declare no conflict of interest.
Funding: The authors are grateful to the financial support from National Science Foundation [Grant no.
TG/2016/Tec-D/02].

Conflicts of Interest: The authors declare no conflict of interest.

References
1.
2.

Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017, 67, 7.
Illouz, F.; Braun, D.; Briet, C.; Schweizer, U.; Rodien, P. Endocrine side-effects of anti-cancer drugs: thyroid
effects of tyrosine kinase inhibitors. Eur. J. Endocrinol. 2014, 171, R91.

Nanomaterials 2019, 9, 208

10 of 11

References
1.
2.
3.
4.

5.
6.

7.

8.

9.

10.
11.
12.

13.

14.
15.
16.

17.
18.

19.

20.

Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer Statistics, 2017. CA Cancer J. Clin. 2017, 67, 7. [CrossRef] [PubMed]
Illouz, F.; Braun, D.; Briet, C.; Schweizer, U.; Rodien, P. Endocrine side-effects of anti-cancer drugs: Thyroid
effects of tyrosine kinase inhibitors. Eur. J. Endocrinol. 2014, 171, R91. [CrossRef] [PubMed]
Monsuez, J.J.; Charniot, J.C.; Vignat, N.; Artigou, J.Y. Cardiac side-effects of cancer chemotherapy.
Int. J. Cardiol. 2010, 144, 3. [CrossRef] [PubMed]
Torino, F.; Barnabei, A.; Paragliola, R.M.; Marchetti, P.; Salvatori, R.; Corsello, S.M. Endocrine side-effects of
anti-cancer drugs: mAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses. Eur. J.
Endocrinol. 2013, 169, R153. [CrossRef] [PubMed]
Amoedo, N.D.; Valencia, J.P.; Rodrigues, M.F.; Galina, A.; Rumjanek, F.D. How does the metabolism of
tumour cells differ from that of normal cells. Biosci. Rep. 2013, 33, e00080. [CrossRef] [PubMed]
Weerasuriya, D.R.K.; Wijesinghe, W.; Rajapakse, R.M.G. Encapsulation of anticancer drug copper
bis(8-hydroxyquinoline) in hydroxyapatite for pH-sensitive targeted delivery and slow release. Mater. Sci.
Eng. C Mater. Biol. Appl. 2017, 71, 206. [CrossRef] [PubMed]
Dunuweera, S.; Rajapakse, R. Synthesis of Unstable Vaterite Polymorph of Porous Calcium Carbonate
Nanoparticles, Encapsulation of Anticancer Drug Cisplatin, Studying Release Kinetics for Safe, Targeted
Delivery and Slow Release. J. Nanomed. Biother. Discov. 2017, 7, 2.
Dunuweera, S.; Rajapakse, R. Encapsulation of anticancer drug cisplatin in vaterite polymorph of calcium
carbonate nanoparticles for targeted delivery and slow release. Biomed. Phys. Eng. Exp. 2017, 4, 015017.
[CrossRef]
Hakeem, A.; Zhan, G.; Xu, Q.; Yong, T.; Yang, X.; Gan, L. Facile synthesis of pH-responsive
doxorubicin-loaded layered double hydroxide for efficient cancer therapy. J. Mater. Chem. B 2018, 6, 5768.
[CrossRef]
Li, L.; Gu, W.; Chen, J.; Chen, W.; Xu, Z.P. Co-delivery of siRNAs and anti-cancer drugs using layered double
hydroxide nanoparticles. Biomaterials 2014, 35, 3331. [CrossRef]
Dhal, J.P.; Sethi, M.; Mishra, B.G.; Hota, G. MgO nanomaterials with different morphologies and their
sorption capacity for removal of toxic dyes. Mater. Lett. 2015, 141, 267. [CrossRef]
Sutradhar, N.; Sinhamahapatra, A.; Pahari, S.K.; Pal, P.; Bajaj, H.C.; Mukhopadhyay, I.; Panda, A.B. Controlled
Synthesis of Different Morphologies of MgO and Their Use as Solid Base Catalysts. J. Phys. Chem. C 2011,
115, 12308. [CrossRef]
Krewski, D.; Yokel, R.A.; Nieboer, E.; Borchelt, D.; Cohen, J.; Harry, J.; Kacew, S.; Lindsay, J.; Mahfouz, A.M.;
Rondeau, V. Human Health Risk Assessment for Aluminium, Aluminium Oxide, and Aluminium Hydroxide.
J. Toxicol. Environ. Health B 2007, 10, 1. [CrossRef] [PubMed]
Pugazhendhi, A.; Edison, T.; Velmurugan, B.K.; Jacob, J.A.; Karuppusamy, I. Toxicity of Doxorubicin (Dox)
to different experimental organ systems. Life Sci. 2018, 200, 26. [CrossRef] [PubMed]
D’Erasmo, E.; Celi, F.S.; Acca, M.; Minisola, S.; Aliberti, G.; Mazzuoli, G.F. Hypocalcemia and
hypomagnesemia in cancer patients. Biomed. Pharmacother. 1991, 45, 315. [CrossRef]
Lopez-Saca, J.M.; Lopez-Picazo, J.M.; Larumbe, A.; Urdiroz, J.; Centeno, C. Hypomagnesemia as a possible
explanation behind episodes of severe pain in cancer patients receiving palliative care. Support. Care Cancer
2013, 21, 649. [CrossRef] [PubMed]
Saris, N.-E.L.; Mervaala, E.; Karppanen, H.; Khawaja, J.A.; Lewenstam, A. Magnesium: An update on
physiological, clinical and analytical aspects. Clin. Chim. Acta 2000, 294, 1. [CrossRef]
Mantilaka, M.; Pitawala, H.; Karunaratne, D.; Rajapakse, R. Nanocrystalline magnesium oxide from dolomite
via poly (acrylate) stabilized magnesium hydroxide colloids. Colloid. Surf. A-Physicochem. Eng. Asp. 2014,
443, 201. [CrossRef]
Mantilaka, M.M.M.G.P.G.; Rajapakse, R.M.G.; Karunaratne, D.G.G.P.; Pitawala, H.M.T.G.A. Preparation of
amorphous calcium carbonate nanoparticles from impure dolomitic marble with the aid of poly(acrylic acid)
as a stabilizer. Adv. Powder Technol. 2014, 25, 591. [CrossRef]
Kokubo, T.; Takadama, H. How useful is SBF in predicting in vivo bone bioactivity? Biomaterials 2006, 27,
2907. [CrossRef]

Nanomaterials 2019, 9, 208

21.

22.
23.

11 of 11

Kamba, S.A.; Ismail, M.; Hussein-Al-Ali, S.H.; Ibrahim, T.A.T.; Zakaria, Z.A.B. In Vitro Delivery and
Controlled Release of Doxorubicin for Targeting Osteosarcoma Bone Cancer. Molecules 2013, 18, 10580.
[CrossRef] [PubMed]
Chandrappa, K.; Venkatesha, T.; Praveen, B.; Shylesha, B. Generation of nanostructured MgO particles by
solution phase method. Res. J. Chem. Sci. 2015, 2231, 606X.
Wu, X.-F.; Hu, G.-S.; Wang, B.-B.; Yang, Y.-F. Synthesis and characterization of superfine magnesium
hydroxide with monodispersity. J. Cryst. Growth 2008, 310, 457. [CrossRef]
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).

